MBLVC logo

MBLVC

Asia, Aichi, Japan, Nagoya

Description

MBLVC is the investment arm of Medical & Biological Laboratories the firm primarily invests in seed.

Investor Profile

MBLVC has made 4 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (50%)
  • Series D (25%)
  • Series B (25%)

Country Focus

  • United States (75%)
  • Japan (25%)

Industry Focus

  • Biotechnology
  • Medical
  • Nursing And Residential Care
  • Health Diagnostics
  • Health Care
  • Therapeutics
  • Bioinformatics
  • Consumer
  • Precision Medicine
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does MBLVC frequently co-invest with?

Boehringer Ingelheim Venture Fund
Europe, Rheinland-Pfalz, Germany, Ingelheim Am Rhein
Co-Investments: 2
CV
North America, Massachusetts, United States, Boston
Co-Investments: 2
Iwagin Jigyo Souzou Capital
Asia, Iwate, Japan, Morioka
Co-Investments: 1
KISCO
Asia, Osaka, Japan, Osaka
Co-Investments: 1
KSP
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Fidea Capital
Asia, Yamagata, Japan, Yamagata
Co-Investments: 1
KNC Laboratories
Asia, Kyoto, Japan, Kobe
Co-Investments: 1
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Mitsubishi UFJ Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Mass Medical Angels
North America, Massachusetts, United States, Boston
Co-Investments: 2

Which angels does MBLVC often collaborate with?

Matthew Winkler
North America, Texas, United States, Austin
Shared Deals: 1

What are some of recent deals done by MBLVC?

J-Pharma

Yokohama, Kanagawa, Japan

J-Pharma is biotechnology company mission is to creating and developing novel pharmaceuticals.

BiotechnologyMedicalNursing and Residential Care
Series DJul 30, 2020
Amount Raised: $16,678
Sentien Biotechnologies

Lexington, Massachusetts, United States

Sentien is a developer of new blood conditioning therapies designed to restore balance to the immune system of critically ill patients.

BiotechnologyHealth CareTherapeutics
Series AApr 4, 2017
Amount Raised: $12,000,000
Second Genome

San Francisco, California, United States

Second Genome offers a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases.

BiotechnologyHealth DiagnosticsMedical
Series BApr 13, 2016
Amount Raised: $51,000,000
Sentieon

Mountain View, California, United States

Enable Precision Data for Precision Medicine

BioinformaticsBiotechnologyConsumerPrecision Medicine
Series AApr 4, 2014
Amount Raised: $3,800,000